International Journal of Cancer Management

Published by: Kowsar

Characterizing of Four Common BCR-ABL Kinase Domain Mutations (T315I, Y253H, M351T and E255K) in Iranian Chronic Myelogenous Leukemia Patients With Imatinib Resistance

Leili Rejali 1 , Behzad Poopak 2 , * , Mandana Hasanzad 3 , Fatemeh Sheikhsofla 4 , Ameneh Saadat Varnoosfaderani 5 , Nazila Safari 6 and Saghar Rabieipoor 7
Authors Information
1 MSc in Molecular Genetics, Islamic Azad University, Tehran Medical Sciences Branch, Tehran, IR Iran
2 DCLS, PhD in Hematology, Islamic Azad University, Tehran Medical Sciences Branch, Tehran, IR Iran
3 PhD in Molecular Genetics, Islamic Azad University, Tehran Medical Sciences Branch, Tehran, IR Iran
4 MSc in Cell and Molecular Biology, Payvand Clinical and Specialty Laboratory, Tehran, IR Iran
5 BSc in Biology, Kawsar Human Genetics Research Centre,Tehran, IR Iran
6 MSc in Molecular Oncology, Payvand Clinical and Specialty,Tehran, IR Iran
7 MSc in Biotechnology, Payvand Clinical and Specialty Laboratory,Tehran, IR Iran
Article information
  • Iranian Journal of Cancer Prevention: May 28, 2015, 8 (3); e2334
  • Published Online: May 27, 2015
  • Article Type: Research Article
  • Received: January 21, 2015
  • Revised: February 1, 2015
  • Accepted: March 10, 2015
  • DOI: 10.17795/ijcp2334

To Cite: Rejali L, Poopak B, Hasanzad M, Sheikhsofla F, Varnoosfaderani A S, et al. Characterizing of Four Common BCR-ABL Kinase Domain Mutations (T315I, Y253H, M351T and E255K) in Iranian Chronic Myelogenous Leukemia Patients With Imatinib Resistance, Int J Cancer Manag. 2015 ; 8(3):e2334. doi: 10.17795/ijcp2334.

Abstract
Copyright © 2015, Iranian Journal of Cancer Prevention.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002; 16(11): 2190-6[DOI][PubMed]
  • 2. Branford S, Hughes TP, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol. 1999; 107(3): 587-99[PubMed]
  • 3. Fausel C. Targeted chronic myeloid leukemia therapy: Seeking a cure. Am J Health Syst Pharm. 2007; 64(24 Suppl 15)-15[DOI][PubMed]
  • 4. Hoffbrand AV, Catovsky D, Tuddenham EGD. Postgraduate Haematology. 2005;
  • 5. Hochhaus A, Saglio G, Larson RA, Kim DW, Etienne G, Rosti G, et al. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood. 2013; 121(18): 3703-8[DOI][PubMed]
  • 6. Quentmeier H, Eberth S, Romani J, Zaborski M, Drexler HG. BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance. J Hematol Oncol. 2011; 4: 6[DOI][PubMed]
  • 7. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007; 110(10): 3540-6[DOI][PubMed]
  • 8. Elias MH, Baba AA, Husin A, Abdullah AD, Hassan R, Sim GA, et al. Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients. Hematol Rep. 2012; 4(4)[DOI][PubMed]
  • 9. Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011; 118(5): 1208-15[DOI][PubMed]
  • 10. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013; 122(6): 872-84[DOI][PubMed]
  • 11. Jones D, Kamel-Reid S, Bahler D, Dong H, Elenitoba-Johnson K, Press R, et al. Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology. J Mol Diagn. 2009; 11(1): 4-11[DOI][PubMed]
  • 12. Hanfstein B, Muller MC, Kreil S, Ernst T, Schenk T, Lorentz C, et al. Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy. Haematologica. 2011; 96(3): 360-6[DOI][PubMed]
  • 13. Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood. 2002; 99(9): 3472-5[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments